News

News 02.11.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present preliminary data from its ongoing Phase...

News 27.10.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial...

Events, External events, News
Event date: 27.08.2024   You can now submit your abstracts for contributed talks, posters, and workshops. The fourth edition of the conference will be held on August 27th and 28th, 2024 at ETH Zurich. It will bring together experts from a variety of disciplines to explore present and future directions in the field of personalized health technologies and...

News 23.10.2023 Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2023 – ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its...

News 19.10.2023 The CUTISS team is proud to announce the recent inauguration of CUTISS Innovation, the French subsidiary of CUTISS AG, at the renowned Sophia Antipolis technology park in France. CUTISS Innovation is supporting and extending our R&D activities in regenerative medicine, including skin pigmentation, aging and healing. The Provence-Alpes-Côte d’Azur region is...